Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Molecular Targeted Therapy
• Oncology Drug Development

Background:

• Molecular-targeted agents represent a significant advancement in treating malignant tumors.
• Sorafenib (Nexavar®) was the first molecular-targeted agent approved for unresectable hepatocellular carcinoma (HCC) in Japan in May 2009.
• Sorafenib is currently the only molecular-targeted agent with demonstrated survival benefits in two global phase III randomized controlled trials, leading to worldwide approval.

Purpose of the Study:

• To review the primary signaling pathways implicated in HCC development and progression.
• To discuss current and emerging molecular-targeted agents for HCC treatment.
• To provide an overview of the current status and future directions in HCC molecular-targeted therapy.

Main Methods:

• Review of existing literature on HCC pathogenesis and molecular-targeted agents.
• Analysis of data from phase III clinical trials, including those comparing sorafenib with other agents.
• Identification of key molecular targets within HCC signaling pathways.

Main Results:

• Sorafenib has established itself as a first-line treatment option for unresectable HCC, supported by robust clinical trial data.
• Several other molecular-targeted agents are under investigation in phase III trials, targeting pathways such as VEGF, PDGF, EGFR, IGF-R, and mTOR.
• These agents represent diverse strategies to inhibit critical signaling cascades driving HCC growth and survival.

Conclusions:

• Molecular-targeted therapy has revolutionized HCC treatment, with sorafenib as a pioneer.
• The ongoing development of novel agents targeting various pathways holds significant promise for improving patient outcomes in HCC.
• Future research will focus on optimizing combination therapies and identifying predictive biomarkers for targeted treatments in HCC.